Vanderbilt Vaccine Center

Chikungunya antibody identified at VUMC moves forward

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.

Julie Carell Stadler, left, Kathryn Carell Brown and Edie Carell Johnson are endowing a new chair in Pediatric Infectious Diseases research at Vanderbilt University School of Medicine.

Carells to endow chair in Pediatric Infectious Diseases

Julie Carell Stadler, Kathryn Carell Brown and Edie Carell Johnson have made a commitment to endow a new chair in Pediatric Infectious Diseases research at Vanderbilt University School of Medicine. The inaugural chair holder of the Edie Carell Johnson Chair in Pediatrics will be announced this spring.

Exploiting viral vulnerabilities

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.

Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award.

VUMC’s resilience amid COVID: Caring for ourselves as we care for others

Caring for ourselves and for one another will be fundamental to the people of Vanderbilt University Medical Center in the coming weeks as COVID-19 is surging, and over the year as the enterprise adapts further to changes while expanding locally and regionally.

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.

COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.

1 3 4 5 6 7 14